In an announcement published on 12 October 2026, hVIVO plc (LSE:HVO) said Angela Hildreth, aged 46, will join as Chief Financial Officer and Board Director with effect from 18 November 2026. She will lead the group's finance function and support a strategy the company …
ConvaTec Group plc (LSE:CTEC) is in focus on 14 October 2026 as investors assess the latest market move and the company’s operating outlook.
Physiomics plc (LSE:PYC) continues to demonstrate operational progress in computational oncology, entering strategic collaborations and deploying its proprietary mathematical modeling software to optimize preclinical and clinical drug development for global biopharmaceutical clients. Quoted on the AIM market of the London Stock Exchange, the computational …
IXICO plc (LSE:IXI) is executing a strategic operational recovery, deploying advanced artificial intelligence neuroimaging algorithms and digital biomarker solutions across global biopharmaceutical clinical trials. Quoted on the AIM market of the London Stock Exchange, the medical technology specialist provides automated brain MRI and PET …
Optima Health plc (LSE:OPT) has achieved transformative operational scale, establishing itself as the undisputed market leader in United Kingdom occupational health and employee clinical wellbeing services following its landmark admission to the London Stock Exchange's AIM market. The healthcare services group provides corporate occupational …
AIM-quoted Abingdon Health plc, a contract developer and manufacturer of lateral flow diagnostics that also provides regulatory services, published final results for the year ended 30 June 2026 (FY26) on 13 October 2026.
AIM-quoted Aptamer Group plc, which develops Optimer binders and works with pharmaceutical, diagnostics and life sciences customers on R&D and licensing programmes, published final results for the twelve months ended 30 June 2026 on 13 October 2026.
Physiomics published its results for the financial year ended 30 June 2026 (FY26). Total income, including grants, rose 26.5% to £1,055,169, compared with £834,156 in FY25. Within that, revenue increased to £941,222 from £784,005.
Thalia Therapeutics PLC (LSE:THAT) has focused its scientific and operational resources on accelerating the preclinical and translational development of novel therapeutic candidates targeting underserved rare genetic conditions. The biopharmaceutical development enterprise identifies molecular targets where monogenic mutations cause severe paediatric or adult degenerative disorders. …
Tristel plc (LSE:TSTL) has reinforced its position as a high-margin, dividend-paying global market leader in infection prevention and medical instrument decontamination. The Cambridgeshire-headquartered company specializes in formulating proprietary chlorine dioxide (ClO2) chemistry. The company's core technology delivers high-level disinfection for non-lumened medical devices—such as …